Home / Recalls / Mylan Pharmaceuticals Inc. / D-0491-2017

D-0491-2017 Class II Terminated

Recalled by Mylan Pharmaceuticals Inc. — Morgantown, WV

Recall Details

Product Type
Drugs
Report Date
March 8, 2017
Initiation Date
January 19, 2017
Termination Date
July 20, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1338 bottles

Product Description

glipiZIDE Extended-Release Tablets, 5 mg, 1000 count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-0342-10

Reason for Recall

Presence of Foreign Tablets/Capsules; bottles of Glipizide 5 mg tablets may contain Glipizide 10 mg tablets

Distribution Pattern

Nationwide

Code Information

Batch # 3074621, June 2018

Other recalls by Mylan Pharmaceuticals Inc.

  • D-0399-2026 Class II — Amnesteem (Isotretinoin) Capsules, USP 40 mg, packaged in 3 x 10-Count Prescript (February 24, 2026)
  • D-0280-2025 Class II — Prasugrel Tablets, USP, 5 mg, 30-count bottle, Rx only, Manufactured for: Mylan (February 25, 2025)
  • D-1292-2022 Class I — Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL p (July 5, 2022)
  • D-0845-2022 Class I — Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packag (April 12, 2022)
  • D-0774-2022 Class II — Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufact (April 7, 2022)
  • D-0748-2022 Class II — Travoprost Ophthalmic Solution, USP, 0.004%, 2.5 mL bottle, Rx only, Manufacture (April 1, 2022)
  • D-0452-2022 Class II — Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topica (January 21, 2022)
  • D-0462-2022 Class I — Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen ( (January 5, 2022)
  • D-0049-2021 Class III — Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packag (October 2, 2020)
  • D-1057-2020 Class III — Tacrolimus Capsules, USP 5mg, 100-count bottle, Rx only, Mylan Pharmaceuticals I (March 23, 2020)